| Epic Health And Wellness Pc | |
|
1075 Cedar Cross Rd Ste 1 Dubuque IA 52003-7748 | |
| (563) 582-1000 | |
| (563) 582-1113 |
| Full Name | Epic Health And Wellness Pc |
|---|---|
| Speciality | Clinic/Center |
| Location | 1075 Cedar Cross Rd Ste 1, Dubuque, Iowa |
| Authorized Official Name and Position | Kelly Mcmahon (CEO) |
| Authorized Official Contact | 5635821000 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Epic Health And Wellness Pc 1075 Cedar Cross Rd Ste 1 Dubuque IA 52003-7748 Ph: (563) 582-1000 | Epic Health And Wellness Pc 1075 Cedar Cross Rd Ste 1 Dubuque IA 52003-7748 Ph: (563) 582-1000 |
| NPI Number | 1164989174 |
|---|---|
| Provider Enumeration Date | 02/26/2019 |
| Last Update Date | 02/26/2019 |
| Medicare PECOS PAC ID | 6901231406 |
|---|---|
| Medicare Enrollment ID | O20200109002833 |
News Archive
Psychiatrists investigating depression have been energized in recent years by reports of rapid, successful treatment with drugs that interfere with the brain chemical glutamate, such as the anesthetic ketamine.
Iverson Genetic Diagnostics today announced the company has received approval from CMS to conduct a WARFARIN Clinical Study. The two-year (2) study will assess the impact of genetic information in calculating doses and the changes in the rate of adverse events when initiating Warfarin drug therapy. These changes will be compared against doses initiated without genetic data. The randomized and blinded, multi-center study will involve more than 7000 participants at over 50 sites nationwide.
Once people develop type 2 diabetes, high blood glucose levels alter their metabolism so much that it becomes difficult to sift through all the clues to find what might enable the disease.
Arena Pharmaceuticals, Inc. today reported pooled Week 52 data from more than 6,000 patients in lorcaserin's pivotal Phase 3 clinical trial program that demonstrate lorcaserin 10 mg dosed twice daily reduced body weight in all patient subgroups evaluated, as defined by gender, age, ethnicity and starting body weight and Body Mass Index (BMI). Greater improvements in cardiovascular risk factors were also achieved with lorcaserin treatment compared to placebo overall and in most subgroups.
› Verified 4 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1164989174 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 261QP2300X | Clinic/center - Primary Care | (* (Not Available)) | Primary |
| Provider Name | Kelly Mcmahon |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1013987189 PECOS PAC ID: 9537159504 Enrollment ID: I20040513000538 |
News Archive
Psychiatrists investigating depression have been energized in recent years by reports of rapid, successful treatment with drugs that interfere with the brain chemical glutamate, such as the anesthetic ketamine.
Iverson Genetic Diagnostics today announced the company has received approval from CMS to conduct a WARFARIN Clinical Study. The two-year (2) study will assess the impact of genetic information in calculating doses and the changes in the rate of adverse events when initiating Warfarin drug therapy. These changes will be compared against doses initiated without genetic data. The randomized and blinded, multi-center study will involve more than 7000 participants at over 50 sites nationwide.
Once people develop type 2 diabetes, high blood glucose levels alter their metabolism so much that it becomes difficult to sift through all the clues to find what might enable the disease.
Arena Pharmaceuticals, Inc. today reported pooled Week 52 data from more than 6,000 patients in lorcaserin's pivotal Phase 3 clinical trial program that demonstrate lorcaserin 10 mg dosed twice daily reduced body weight in all patient subgroups evaluated, as defined by gender, age, ethnicity and starting body weight and Body Mass Index (BMI). Greater improvements in cardiovascular risk factors were also achieved with lorcaserin treatment compared to placebo overall and in most subgroups.
› Verified 4 days ago
| Provider Name | Amanda A Renne |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1942857529 PECOS PAC ID: 1052640141 Enrollment ID: I20210203002161 |
News Archive
Psychiatrists investigating depression have been energized in recent years by reports of rapid, successful treatment with drugs that interfere with the brain chemical glutamate, such as the anesthetic ketamine.
Iverson Genetic Diagnostics today announced the company has received approval from CMS to conduct a WARFARIN Clinical Study. The two-year (2) study will assess the impact of genetic information in calculating doses and the changes in the rate of adverse events when initiating Warfarin drug therapy. These changes will be compared against doses initiated without genetic data. The randomized and blinded, multi-center study will involve more than 7000 participants at over 50 sites nationwide.
Once people develop type 2 diabetes, high blood glucose levels alter their metabolism so much that it becomes difficult to sift through all the clues to find what might enable the disease.
Arena Pharmaceuticals, Inc. today reported pooled Week 52 data from more than 6,000 patients in lorcaserin's pivotal Phase 3 clinical trial program that demonstrate lorcaserin 10 mg dosed twice daily reduced body weight in all patient subgroups evaluated, as defined by gender, age, ethnicity and starting body weight and Body Mass Index (BMI). Greater improvements in cardiovascular risk factors were also achieved with lorcaserin treatment compared to placebo overall and in most subgroups.
› Verified 4 days ago
News Archive
Psychiatrists investigating depression have been energized in recent years by reports of rapid, successful treatment with drugs that interfere with the brain chemical glutamate, such as the anesthetic ketamine.
Iverson Genetic Diagnostics today announced the company has received approval from CMS to conduct a WARFARIN Clinical Study. The two-year (2) study will assess the impact of genetic information in calculating doses and the changes in the rate of adverse events when initiating Warfarin drug therapy. These changes will be compared against doses initiated without genetic data. The randomized and blinded, multi-center study will involve more than 7000 participants at over 50 sites nationwide.
Once people develop type 2 diabetes, high blood glucose levels alter their metabolism so much that it becomes difficult to sift through all the clues to find what might enable the disease.
Arena Pharmaceuticals, Inc. today reported pooled Week 52 data from more than 6,000 patients in lorcaserin's pivotal Phase 3 clinical trial program that demonstrate lorcaserin 10 mg dosed twice daily reduced body weight in all patient subgroups evaluated, as defined by gender, age, ethnicity and starting body weight and Body Mass Index (BMI). Greater improvements in cardiovascular risk factors were also achieved with lorcaserin treatment compared to placebo overall and in most subgroups.
› Verified 4 days ago
Unitypoint Clinic Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 350 N Grandview Ave, Dubuque, IA 52001 Phone: 563-589-2612 Fax: 563-589-2648 | |
Balance Integrative Health & Wellness Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 4855 Asbury Rd, Ste #7, Dubuque, IA 52002 Phone: 563-284-2422 | |
Burger Chiropractic L.l.c Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 989 Langworthy St Ste 202, Dubuque, IA 52001 Phone: 563-582-1188 Fax: 563-582-1181 | |
Wellspring Health Llc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 1550 University Ave, Dubuque, IA 52001 Phone: 563-900-8300 | |
Dr. Gene Noonan Inc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 1641 Asbury Rd, Dubuque, IA 52001 Phone: 563-556-8464 Fax: 563-556-0879 | |
Hillcrest Family Services Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 220 W 7th St, Dubuque, IA 52001 Phone: 563-583-6431 Fax: 563-557-4447 |